CN100352505C - 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合 - Google Patents

治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合 Download PDF

Info

Publication number
CN100352505C
CN100352505C CNB998163562A CN99816356A CN100352505C CN 100352505 C CN100352505 C CN 100352505C CN B998163562 A CNB998163562 A CN B998163562A CN 99816356 A CN99816356 A CN 99816356A CN 100352505 C CN100352505 C CN 100352505C
Authority
CN
China
Prior art keywords
alkyl
aryl
pharmaceutical composition
group
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998163562A
Other languages
English (en)
Chinese (zh)
Other versions
CN1350466A (zh
Inventor
M·D·埃里安
P·范佩耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of CN1350466A publication Critical patent/CN1350466A/zh
Application granted granted Critical
Publication of CN100352505C publication Critical patent/CN100352505C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB998163562A 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合 Expired - Fee Related CN100352505C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
US60/114,718 1998-12-24
US60/114718 1998-12-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100806150A Division CN1714866A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CNA2007101628889A Division CN101164618A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合

Publications (2)

Publication Number Publication Date
CN1350466A CN1350466A (zh) 2002-05-22
CN100352505C true CN100352505C (zh) 2007-12-05

Family

ID=22357016

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB998163562A Expired - Fee Related CN100352505C (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CNA2005100806150A Pending CN1714866A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CNA2007101628889A Pending CN101164618A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2005100806150A Pending CN1714866A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CNA2007101628889A Pending CN101164618A (zh) 1998-12-24 1999-12-22 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合

Country Status (25)

Country Link
EP (1) EP1143955B1 (enExample)
JP (1) JP2003515523A (enExample)
KR (3) KR100689943B1 (enExample)
CN (3) CN100352505C (enExample)
AT (1) ATE300288T1 (enExample)
AU (1) AU771039B2 (enExample)
BR (1) BR9917005A (enExample)
CA (1) CA2354053A1 (enExample)
CZ (1) CZ20012353A3 (enExample)
DE (1) DE69926400T2 (enExample)
DK (1) DK1143955T3 (enExample)
ES (1) ES2246586T3 (enExample)
HK (1) HK1046863B (enExample)
HU (1) HUP0402506A3 (enExample)
ID (1) ID30237A (enExample)
IL (2) IL143569A0 (enExample)
MX (1) MXPA01006511A (enExample)
NO (1) NO20013115L (enExample)
NZ (1) NZ512219A (enExample)
PL (1) PL352756A1 (enExample)
PT (1) PT1143955E (enExample)
RU (2) RU2227749C2 (enExample)
SK (1) SK9172001A3 (enExample)
WO (1) WO2000038666A2 (enExample)
ZA (1) ZA200105016B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CN1740182A (zh) * 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
EP1607401A1 (en) * 2000-03-08 2005-12-21 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-Bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN101301294A (zh) * 2000-07-06 2008-11-12 症变治疗公司 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
WO2004022083A1 (en) * 2002-09-04 2004-03-18 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
TWI349550B (en) 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
EP1778250A2 (en) * 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
CN101115483A (zh) * 2004-12-15 2008-01-30 第一三共株式会社 含有FBPase抑制剂的药物组合物
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
CN1145783A (zh) * 1995-06-20 1997-03-26 武田药品工业株式会社 药物组合物
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
CN1145783A (zh) * 1995-06-20 1997-03-26 武田药品工业株式会社 药物组合物
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
HK1046863A1 (zh) 2003-01-30
CN1714866A (zh) 2006-01-04
HUP0402506A2 (hu) 2005-04-28
PL352756A1 (en) 2003-09-08
NO20013115D0 (no) 2001-06-21
KR20070046210A (ko) 2007-05-02
IL143569A0 (en) 2002-04-21
CN101164618A (zh) 2008-04-23
EP1143955A3 (en) 2002-08-28
MXPA01006511A (es) 2004-03-19
KR20060114724A (ko) 2006-11-07
SK9172001A3 (en) 2002-04-04
JP2003515523A (ja) 2003-05-07
CZ20012353A3 (cs) 2001-12-12
HK1046863B (zh) 2008-07-25
ID30237A (id) 2001-11-15
IL143569A (en) 2006-06-11
BR9917005A (pt) 2002-04-02
PT1143955E (pt) 2005-11-30
ES2246586T3 (es) 2006-02-16
WO2000038666A2 (en) 2000-07-06
DK1143955T3 (da) 2005-11-14
HUP0402506A3 (en) 2007-05-29
NZ512219A (en) 2004-12-24
RU2227749C2 (ru) 2004-04-27
NO20013115L (no) 2001-08-24
EP1143955A2 (en) 2001-10-17
KR100689943B1 (ko) 2007-03-08
WO2000038666A3 (en) 2001-11-29
CA2354053A1 (en) 2000-07-06
ATE300288T1 (de) 2005-08-15
CN1350466A (zh) 2002-05-22
DE69926400T2 (de) 2006-05-24
AU771039B2 (en) 2004-03-11
DE69926400D1 (de) 2005-09-01
KR20010099942A (ko) 2001-11-09
RU2003132054A (ru) 2005-04-20
ZA200105016B (en) 2002-09-19
AU2058300A (en) 2000-07-31
EP1143955B1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
EP1143955B1 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
KR100875335B1 (ko) 신규 비스아미데이트 포스포네이트 프로드러그
RU2328308C2 (ru) Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HK1075622A (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
AU2003242500C1 (en) Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1046863

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071205

Termination date: 20181222